Before And After Measurements Using Laser Profilometry Prove Wrinkle
NEW YORK, Nov. 5 /PRNewswire/ -- DermaPlus, Inc., makers of DermaLastyl anti-aging skin creams, announced today the preliminary results of their 12-week clinical trial on the anti-aging effects of its skin creams. Renowned, anti-aging doctor, Dr. Steven Lamm, oversaw the study, in which 35 volunteers were imaged by a sophisticated technique called laser profilometry before and after using DermaLastyl for 12 weeks. The profilometry data and digital photographs were analyzed by computers to compare a series of parameters such as roughness, length and depth of wrinkles. The study results showed significant improvements in all parameters: 83% of the participants showed significant improvement in skin smoothness and reduction in the appearance of fines lines and wrinkles. (Study results provided upon request.)
The key ingredient in DermaLastyl products is Elastatropin, a synthetic form of natural elastin. Elastin, the second most abundant protein in the body, is responsible for the elasticity of skin and organs, and its degradation is a well-known irreversible cause of wrinkles. DermaLastyl is revolutionary because it is the first cosmetic product ever to contain a complete functional human protein. DermaPlus synthesized the human Tropoelastin gene and uses this DNA to laboratory manufacture its own Elastatropin brand of human elastin. The study now provides unequivocal proof that topical application of DermaLastyl reduces the appearance of current wrinkles, and helps prevent the formation of new ones.
Noted microbiologist Dr. Burt Ensley, CEO of DermaPlus, Inc., said: "After introducing our products, we were challenged in news reports by Dr. Amy Neuberger and Dr. Lamm to provide objective evidence to support our claims, especially since most skin cream vendors advertise the results of consumer self-evaluation studies that are completely subjective and unscientific. Now we have irrefutable evidence support for our efficacy claims using the most sophisticated and quantitative measurement technology available today."
"We are delighted with the results of the study, as it clearly demonstrates 2.5x better results than a similar study done using Botox alone," added Dr. Ensley. "Building on that success, our long term objective is to generate sufficient revenue to advance the use of Elastatropin for both wound healing and tissue regeneration. Since Elastatropin was developed in response to a War Wound Research Project, we hope to one day return Elastatropin to its original medical purpose."
DermaLastyl is not yet available in stores but can be purchased on the web at http://www.dermaLastyl.com or by calling 800-335-8312. Distribution will be expanded to include retail and department stores worldwide in the coming months.
About DermaPlus, Inc.
DermaPlus, Inc., the producer of DermaLastyl line of products, is a biotechnology company that designs and manufactures sophisticated, high performance biomaterials Tropoelastin and Keratin for use in cosmeceuticals. Based on human genetic sequences, these biomaterials can be customized to reflect the genetic makeup of human tissues, population groups or even single individuals. DermaLastyl-B, DermaLastyl-E, and Derma-Lastyl-Bx are the first genetically engineered products on the market that help restore elastic properties to the skin. Used properly, DermaLastyl will eliminate and/or prevent wrinkles, reducing the need or extending the life of cosmetic medical procedures such as for Botox or facelifts.
Dr. Burt Ensley is a Sedona, AZ-based biotechnology scientist specializing in the synthesis and use of Matrix Proteins that define the structure of skin and organs. He is an Adjunct Professor at the Bio 5 Institute, University of Arizona and the inventor on 16 issued patents in the filed of biotechnology.
Dr. Steven Lamm is the author of several books on health and aging. An internist, he is an Assistant Professor of Medicine at New York University School of Medicine, in addition to maintaining a private practice in New York City.
|SOURCE DermaPlus, Inc.|
Copyright©2007 PR Newswire.
All rights reserved